Dr. Reddy's Laboratories (NYSE: RDY) announced today that it has
launched Montelukast Sodium Oral Granules, a bioequivalent generic
version of Singulair® (montelukast sodium) oral granules in the US
market on September, 26, 2012, following the approval by the United
States Food & Drug Administration (USFDA) of Dr.Reddy's ANDA for
Montelukast Sodium Oral Granules.
The Singulair® Oral Granules brand had U.S. sales
of approximately $61 million for the most recent twelve months ending
July 2012 according to IMS Health*.
Dr. Reddy's Montelukast Sodium Oral Granules in 4 mg are available in
unit dosage package of 30.